Who is sponsoring NCT03639077?

NCT03639077 is sponsored by University of Oklahoma.

What drugs are being tested in NCT03639077?

Interventions in NCT03639077: Allograft bone alone, Allograft and xenograft mixture.

What condition does NCT03639077 study?

NCT03639077 studies Lateral Window Sinus Augmentation.

Is NCT03639077 still recruiting?

NCT03639077 is currently completed. Last updated 19 March 2024.

Last reviewed 2024-03-19 · How we verify

NCT03639077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Volumetric Changes and Graft Stability in Lateral Window Sinus Augmentation: A Prospective Clinical Trial

Completed NA Last updated 19 March 2024

What this trial tests

NA trial testing Allograft bone alone in Lateral Window Sinus Augmentation in 19 participants. Completed in 9 September 2020.

Timeline

1 October 2018

Primary endpoint
24 April 2019

9 September 2020

Quick facts

Lead sponsor	University of Oklahoma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	19
Start date	1 October 2018
Primary completion	24 April 2019
Estimated completion	9 September 2020
Sites	1 location across United States

Drugs / interventions tested

Allograft bone alone
Allograft and xenograft mixture

Conditions studied

Lateral Window Sinus Augmentation — all drugs for Lateral Window Sinus Augmentation →

Sponsor

University of Oklahoma

Who can join

18 and older, any sex, with Lateral Window Sinus Augmentation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the stability and volumetric changes of the grafting materials used for lateral window sinus augmentation. In addition, different variables known to affect bone stability and remodeling with regard to the augmentation procedure will be evaluated. Similarly, implant placement will be performed and results will be evaluated after a period of six months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Oklahoma trials

Trials by the same sponsor.

NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03639077 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
Last refreshed: 19 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03639077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing